Gonadotropin-Releasing Hormone Agonist Versus Recombinant Human Chorionic Gonadotropin Triggering in Fertility Preservation Cycles.
Cancer patients
Elective fertility preservation
Onco-fertility preservation
Oocyte cryopreservation
Ovarian stimulation
Journal
Reproductive sciences (Thousand Oaks, Calif.)
ISSN: 1933-7205
Titre abrégé: Reprod Sci
Pays: United States
ID NLM: 101291249
Informations de publication
Date de publication:
12 2021
12 2021
Historique:
received:
01
04
2021
accepted:
13
05
2021
pubmed:
3
6
2021
medline:
11
3
2022
entrez:
2
6
2021
Statut:
ppublish
Résumé
The purpose of this research is to study the efficacy of GnRH-a versus r-hCG triggering in patients who go through fertility preservation cycles. This retrospective cohort study was performed in a tertiary university-affiliated medical center. It includes 191 patients undergoing fertility preservation cycles between May 2013 and September 2018, in which ovulation was induced by either GnRH-a or r-hCG. Main outcome measures were number and rate of mature oocyte. Among treatment cycles with medical indication, GnRH agonist significantly increases the odds for high mature rate by 3.55 (1.30-9.66), while in treatment cycles with social indication, there is no significant effect of the triggering agent. An advantage for GnRH-a triggering was observed in medically indicated preservation cycles.
Identifiants
pubmed: 34076872
doi: 10.1007/s43032-021-00622-2
pii: 10.1007/s43032-021-00622-2
doi:
Substances chimiques
Chorionic Gonadotropin
0
Recombinant Proteins
0
Triptorelin Pamoate
08AN7WA2G0
Gonadotropin-Releasing Hormone
33515-09-2
Types de publication
Comparative Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
3390-3396Informations de copyright
© 2021. Society for Reproductive Investigation.
Références
Ubaldi FM, Cimadomo D, Vaiarelli A, Fabozzi G, Venturella R, Maggiulli R, et al. Advanced maternal age in IVF: still a challenge? The Present and the Future of Its Treatment. Front Endocrinol (Lausanne). 2019;10:94. https://doi.org/10.3389/fendo.2019.00094 .
doi: 10.3389/fendo.2019.00094
Oktay K, Harvey BE, Loren AW. Fertility preservation in patients with cancer: ASCO clinical practice guideline update summary. J Oncol Pract. 2018;14(6):381–5. https://doi.org/10.1200/JOP.18.00160 .
doi: 10.1200/JOP.18.00160
pubmed: 29768110
Rienzi L, Gracia C, Maggiulli R, LaBarbera AR, Kaser DJ, Ubaldi FM, et al. Oocyte, embryo and blastocyst cryopreservation in ART: systematic review and meta-analysis comparing slow-freezing versus vitrification to produce evidence for the development of global guidance. Hum Reprod Update. 2017;23(2):139–55. https://doi.org/10.1093/humupd/dmw038 .
doi: 10.1093/humupd/dmw038
Humaidan P, Bredkjaer HE, Bungum L, Bungum M, Grondahl ML, Westergaard L, et al. GnRH agonist (buserelin) or hCG for ovulation induction in GnRH antagonist IVF/ICSI cycles: a prospective randomized study. Hum Reprod. 2005;20(5):1213–20. https://doi.org/10.1093/humrep/deh765 .
doi: 10.1093/humrep/deh765
pubmed: 15760966
Babayof R, Margalioth EJ, Huleihel M, Amash A, Zylber-Haran E, Gal M, et al. Serum inhibin A, VEGF and TNFalpha levels after triggering oocyte maturation with GnRH agonist compared with HCG in women with polycystic ovaries undergoing IVF treatment: a prospective randomized trial. Hum Reprod. 2006;21(5):1260–5. https://doi.org/10.1093/humrep/dei475 .
doi: 10.1093/humrep/dei475
pubmed: 16439507
Youssef MA, Van der Veen F, Al-Inany HG, Mochtar MH, Griesinger G, Nagi Mohesen M, et al. Gonadotropin-releasing hormone agonist versus HCG for oocyte triggering in antagonist-assisted reproductive technology. Cochrane Database Syst Rev. 2014;10:CD008046. https://doi.org/10.1002/14651858.CD008046.pub4 .
doi: 10.1002/14651858.CD008046.pub4
Delvigne A, Rozenberg S. Epidemiology and prevention of ovarian hyperstimulation syndrome (OHSS): a review. Hum Reprod Update. 2002;8(6):559–77. https://doi.org/10.1093/humupd/8.6.559 .
doi: 10.1093/humupd/8.6.559
pubmed: 12498425
Weissman A, Lurie S, Zalel Y, Goldchmit R, Shoham Z. Human chorionic gonadotropin: pharmacokinetics of subcutaneous administration. Gynecol Endocrinol. 1996;10(4):273–6. https://doi.org/10.3109/09513599609012319 .
doi: 10.3109/09513599609012319
pubmed: 8908528
Bodri D, Guillen JJ, Galindo A, Mataro D, Pujol A, Coll O. Triggering with human chorionic gonadotropin or a gonadotropin-releasing hormone agonist in gonadotropin-releasing hormone antagonist-treated oocyte donor cycles: findings of a large retrospective cohort study. Fertil Steril. 2009;91(2):365–71. https://doi.org/10.1016/j.fertnstert.2007.11.049 .
doi: 10.1016/j.fertnstert.2007.11.049
pubmed: 18367175
Engmann L, DiLuigi A, Schmidt D, Nulsen J, Maier D, Benadiva C. The use of gonadotropin-releasing hormone (GnRH) agonist to induce oocyte maturation after cotreatment with GnRH antagonist in high-risk patients undergoing in vitro fertilization prevents the risk of ovarian hyperstimulation syndrome: a prospective randomized controlled study. Fertil Steril. 2008;89(1):84–91. https://doi.org/10.1016/j.fertnstert.2007.02.002 .
doi: 10.1016/j.fertnstert.2007.02.002
pubmed: 17462639
Humaidan P, Alsbjerg B. GnRHa trigger for final oocyte maturation: is HCG trigger history? Reprod BioMed Online. 2014;29(3):274–80. https://doi.org/10.1016/j.rbmo.2014.05.008 .
doi: 10.1016/j.rbmo.2014.05.008
pubmed: 25043893
Engmann L, Benadiva C. Agonist trigger: what is the best approach? Agonist trigger with aggressive luteal support. Fertil Steril. 2012;97(3):531–3. https://doi.org/10.1016/j.fertnstert.2011.12.020 .
doi: 10.1016/j.fertnstert.2011.12.020
pubmed: 22245529
Meyer L, Murphy LA, Gumer A, Reichman DE, Rosenwaks Z, Cholst IN. Risk factors for a suboptimal response to gonadotropin-releasing hormone agonist trigger during in vitro fertilization cycles. Fertil Steril. 2015;104(3):637–42. https://doi.org/10.1016/j.fertnstert.2015.06.011 .
doi: 10.1016/j.fertnstert.2015.06.011
pubmed: 26149355
Chang FE, Beall SA, Cox JM, Richter KS, DeCherney AH, Levy MJ. Assessing the adequacy of gonadotropin-releasing hormone agonist leuprolide to trigger oocyte maturation and management of inadequate response. Fertil Steril. 2016;106(5):1093–100 e3. https://doi.org/10.1016/j.fertnstert.2016.06.013 .
doi: 10.1016/j.fertnstert.2016.06.013
pubmed: 27341988
Chen SL, Ye DS, Chen X, Yang XH, Zheng HY, Tang Y, et al. Circulating luteinizing hormone level after triggering oocyte maturation with GnRH agonist may predict oocyte yield in flexible GnRH antagonist protocol. Hum Reprod. 2012;27(5):1351–6. https://doi.org/10.1093/humrep/des049 .
doi: 10.1093/humrep/des049
pubmed: 22419746
Shapiro BS, Daneshmand ST, Restrepo H, Garner FC, Aguirre M, Hudson C. Efficacy of induced luteinizing hormone surge after “trigger” with gonadotropin-releasing hormone agonist. Fertil Steril. 2011;95(2):826–8. https://doi.org/10.1016/j.fertnstert.2010.09.009 .
doi: 10.1016/j.fertnstert.2010.09.009
pubmed: 20961539
Rodgers RJ, Reid GD, Koch J, Deans R, Ledger WL, Friedlander M, et al. The safety and efficacy of controlled ovarian hyperstimulation for fertility preservation in women with early breast cancer: a systematic review. Hum Reprod. 2017;32(5):1033–45. https://doi.org/10.1093/humrep/dex027 .
doi: 10.1093/humrep/dex027
pubmed: 28333356
Engmann L, Benadiva C, Humaidan P. GnRH agonist trigger for the induction of oocyte maturation in GnRH antagonist IVF cycles: a SWOT analysis. Reprod BioMed Online. 2016;32(3):274–85. https://doi.org/10.1016/j.rbmo.2015.12.007 .
doi: 10.1016/j.rbmo.2015.12.007
pubmed: 26803205
Iliodromiti S, Blockeel C, Tremellen KP, Fleming R, Tournaye H, Humaidan P, et al. Consistent high clinical pregnancy rates and low ovarian hyperstimulation syndrome rates in high-risk patients after GnRH agonist triggering and modified luteal support: a retrospective multicentre study. Hum Reprod. 2013;28(9):2529–36. https://doi.org/10.1093/humrep/det304 .
doi: 10.1093/humrep/det304
pubmed: 23873146
Makhijani R, Thorne J, Bartels C, Bartolucci A, Nulsen J, Grow D, et al. Pregnancy outcomes after frozen-thawed single euploid blastocyst transfer following IVF cycles using GNRH agonist or HCG trigger for final oocyte maturation. J Assist Reprod Genet. 2020;37(3):611–7. https://doi.org/10.1007/s10815-019-01646-z .
doi: 10.1007/s10815-019-01646-z
pubmed: 31897845
pmcid: 7125271
Thorne J, Loza A, Kaye L, Nulsen J, Benadiva C, Grow D, et al. Euploidy rates between cycles triggered with gonadotropin-releasing hormone agonist and human chorionic gonadotropin. Fertil Steril. 2019;112(2):258–65. https://doi.org/10.1016/j.fertnstert.2019.03.040 .
doi: 10.1016/j.fertnstert.2019.03.040
pubmed: 31103285
Humaidan P, Papanikolaou EG, Kyrou D, Alsbjerg B, Polyzos NP, Devroey P, et al. The luteal phase after GnRH-agonist triggering of ovulation: present and future perspectives. Reprod BioMed Online. 2012;24(2):134–41. https://doi.org/10.1016/j.rbmo.2011.11.001 .
doi: 10.1016/j.rbmo.2011.11.001
pubmed: 22197130
Reddy J, Turan V, Bedoschi G, Moy F, Oktay K. Triggering final oocyte maturation with gonadotropin-releasing hormone agonist (GnRHa) versus human chorionic gonadotropin (hCG) in breast cancer patients undergoing fertility preservation: an extended experience. J Assist Reprod Genet. 2014;31(7):927–32. https://doi.org/10.1007/s10815-014-0248-6 .
doi: 10.1007/s10815-014-0248-6
pubmed: 24854484
pmcid: 4096878
Pereira N, Kelly AG, Stone LD, Witzke JD, Lekovich JP, Elias RT, et al. Gonadotropin-releasing hormone agonist trigger increases the number of oocytes and embryos available for cryopreservation in cancer patients undergoing ovarian stimulation for fertility preservation. Fertil Steril. 2017;108(3):532–8. https://doi.org/10.1016/j.fertnstert.2017.06.027 .
doi: 10.1016/j.fertnstert.2017.06.027
pubmed: 28865552
Kim J, Turan V, Oktay K. Long-term safety of letrozole and gonadotropin stimulation for fertility preservation in women with breast cancer. J Clin Endocrinol Metab. 2016;101(4):1364–71. https://doi.org/10.1210/jc.2015-3878 .
doi: 10.1210/jc.2015-3878
pubmed: 26751194
pmcid: 4880171
Sonigo C, Sermondade N, Calvo J, Benard J, Sifer C, Grynberg M. Impact of letrozole supplementation during ovarian stimulation for fertility preservation in breast cancer patients. Eur J Obstet Gynecol Reprod Biol X. 2019;4:100049. https://doi.org/10.1016/j.eurox.2019.100049 .
doi: 10.1016/j.eurox.2019.100049
pubmed: 31673686
pmcid: 6817658
Goldrat O, Van Den Steen G, Gonzalez-Merino E, Dechene J, Gervy C, Delbaere A, et al. Letrozole-associated controlled ovarian hyperstimulation in breast cancer patients versus conventional controlled ovarian hyperstimulation in infertile patients: assessment of oocyte quality related biomarkers. Reprod Biol Endocrinol. 2019;17(1):3. https://doi.org/10.1186/s12958-018-0443-x .
doi: 10.1186/s12958-018-0443-x
pubmed: 30606204
pmcid: 6318989
Galindo A, Bodri D, Guillen JJ, Colodron M, Vernaeve V, Coll O. Triggering with HCG or GnRH agonist in GnRH antagonist treated oocyte donation cycles: a randomised clinical trial. Gynecol Endocrinol. 2009;25(1):60–6. https://doi.org/10.1080/09513590802404013 .
doi: 10.1080/09513590802404013
pubmed: 19165664
Melo M, Busso CE, Bellver J, Alama P, Garrido N, Meseguer M, et al. GnRH agonist versus recombinant HCG in an oocyte donation programme: a randomized, prospective, controlled, assessor-blind study. Reprod BioMed Online. 2009;19(4):486–92. https://doi.org/10.1016/j.rbmo.2009.06.001 .
doi: 10.1016/j.rbmo.2009.06.001
pubmed: 19909588
Sismanoglu A, Tekin HI, Erden HF, Ciray NH, Ulug U, Bahceci M. Ovulation triggering with GnRH agonist vs. hCG in the same egg donor population undergoing donor oocyte cycles with GnRH antagonist: a prospective randomized cross-over trial. J Assist Reprod Genet. 2009;26(5):251–6. https://doi.org/10.1007/s10815-009-9326-6 .
doi: 10.1007/s10815-009-9326-6
pubmed: 19629674
pmcid: 2719073
Cobo A, Garcia-Velasco J, Domingo J, Pellicer A, Remohi J. Elective and onco-fertility preservation: factors related to IVF outcomes. Hum Reprod. 2018;33(12):2222–31. https://doi.org/10.1093/humrep/dey321 .
doi: 10.1093/humrep/dey321
pubmed: 30383235